The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Erminia Massarelli
No relevant relationships to disclose
Lawrence E. Ginsberg
No relevant relationships to disclose
Heather Lin
No relevant relationships to disclose
Hai T. Tran
No relevant relationships to disclose
J. Jack Lee
No relevant relationships to disclose
Michelle D. Williams
No relevant relationships to disclose
George R. Blumenschein
No relevant relationships to disclose
Charles Lu
No relevant relationships to disclose
Merrill S. Kies
No relevant relationships to disclose
Vassiliki Papadimitrakopoulou
Research Funding - Astellas Pharma; Novartis